vimarsana.com

Latest Breaking News On - Xortx therapeutics inc stock exchange - Page 1 : vimarsana.com

XORTX Therapeutics : NOTICE OF ANNUAL & SPECIAL MEETING OF SHAREHOLDERS - Form 6-K

NOTICE OF ANNUAL & SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the annual and special meeting of the shareholders of XORTX Therapeutics Inc. will be held. | May 30, 2023

Anthony giovinazzoTherapeutics incCompany commonRecord dateCommon sharesXortx therapeutics inc stock exchangePress releaseE xrtx ca98420q2071

XORTX Therapeutics : Annual Information Form

XORTX THERAPEUTICS INC. ANNUAL INFORMATION FORM FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 MARCH 31, 2023 . | April 1, 2023

United statesTherapeutics incOrphan drug designationXortx therapeutics inc stock exchangePress releaseArch xrtx ca98420q2071

XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial

CALGARY, Alberta, Jan. 19, 2023 XORTX Therapeutics Inc. , a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is. | January 19, 2023

United statesNick rigopulosAllen davidoffDavid melamedCompany xrxTherapeutics incBridging pharmacokinetics clinical trialKidney diseasePolycystic kidney diseaseNat rev disNat rev nephrolXortx therapeutics inc stock exchangePress releaseIdney xrtx ca98420q2071

XORTX Presents New Proof of Concept Data at American Society of Nephrology

● Xanthine Oxidase Inhibition with XRx-008 Blocks Uric Acid Induced Increasein Total Kidney Weight in Polycystic Kidney Disease ● CALGARY, Alberta, Nov. 03, 2022 XORTX. | November 3, 2022

United statesAllen davidoffCharles edelsteinCompany xrxAssociation of nephrolithiasisUniversity of coloradoTherapeutics incAmerican society of nephrologyVenture exchangeXanthine oxidase inhibitionUric acid inducedTotal kidney weightPolycystic kidney diseaseAmerican societyAnnual conferenceSerum uric acid

XORTX to Present at LD Micro Invitational 2022

CALGARY, Alberta, June 08, 2022 XORTX Therapeutics Inc. , a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased. | June 8, 2022

Nick rigopulosAllen davidoffExchange commissionTherapeutics incSeasons hotel westlake villageVenture exchangeGlobenewswire incAutosomal dominant polycystic kidney diseaseAnnual information formManagement discussionXortx therapeutics inc stock exchangePress releaseS xrtx ca98420q2071

vimarsana © 2020. All Rights Reserved.